Dual variable region antibody-like binding proteins having cross-over binding region orientation

1. An antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, wherein two polypeptide chains have a structure represented by the formula:

V L1 -L 1 -V L2 -L 2 -C L   [I]

and two polypeptide chains have a structure represented by the formula:

V H2 -L 3 -V H1 -L 4 -C H1 -Fc  [II]

wherein:

V L1 is a first immunoglobulin light chain variable domain;

V L2 is a second immunoglobulin light chain variable domain;

V H1 is a first immunoglobulin heavy chain variable domain;

V H2 is a second immunoglobulin heavy chain variable domain;

C L is an immunoglobulin light chain constant domain;

C H1 is the immunoglobulin C H1 heavy chain constant domain;

Fc is the immunoglobulin hinge region and C H2 , C H3 immunoglobulin heavy chain constant domains; and

L 1 , L 2 , L 3 , and L 4 are amino acid linkers;

wherein L 2 and L 4 are both at least one amino acid in length, and

(a) the length of L 2 is at least twice the length of L 4 ; or

(b) the length of L 4 is at least twice the length of L 2 ;

and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

2. An antibody-like binding protein comprising two polypeptide chains that form two antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:

V L1 -L 1 -V L2 -L 2 -C L   [I]

and a second polypeptide chain has a structure represented by the formula:

V H2 -L 3 -V H1 -L 4 -C H1   [II]

wherein:

V L1 is a first immunoglobulin light chain variable domain;

V L2 is a second immunoglobulin light chain variable domain;

V H1 is a first immunoglobulin heavy chain variable domain;

V H2 is a second immunoglobulin heavy chain variable domain;

C L is an immunoglobulin light chain constant domain;

C H1 is the immunoglobulin C H1 heavy chain constant domain; and

L 1 , L 2 , L 3 , and L 4 are amino acid linkers;

wherein L 2 and L 4 are both at least one amino acid in length, and

(a) the length of L 2 is at least twice the length of L 4 ; or

(b) the length of L 4 is at least twice the length of L 2 ;

and wherein the first and second polypeptides form a cross-over light chain-heavy chain pair.

3. The antibody-like binding protein of claim 1 , wherein L 1 and L 3 are both at least one amino acid in length; and

wherein the length of L 1 is at least twice the length of L 3 if the length of L 2 is at least twice the length of L 4 ; or

the length of L 3 is at least twice the length of L 1 if the length of L 4 is at least twice the length of L 2 .

4. The antibody-like binding protein of claim 2 , wherein L 1 and L 3 are both at least one amino acid in length; and

wherein the length of L 1 is at least twice the length of L 3 if the length of L 2 is at least twice the length of L 4 ; or

the length of L 3 is at least twice the length of L 1 if the length of L 4 is at least twice the length of L 2 .

5. An antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, wherein two polypeptide chains have a structure represented by the formula:

V L1 -L 1 -V L2 -L 2 -C L   [I]

and two polypeptide chains have a structure represented by the formula:

V H2 -L 3 -V H1 -L 4 -C H1 -Fc  [II]

wherein:

V L1 is a first immunoglobulin light chain variable domain;

V L2 is a second immunoglobulin light chain variable domain;

V H1 is a first immunoglobulin heavy chain variable domain;

V H2 is a second immunoglobulin heavy chain variable domain;

C L is an immunoglobulin light chain constant domain;

C H1 is the immunoglobulin C H1 heavy chain constant domain;

Fc is the immunoglobulin hinge region and C H2 , C H3 immunoglobulin heavy chain constant domains; and

L 1 , L 2 , L 3 , and L 4 are amino acid linkers;

wherein:

L 1 is 3 to 12 amino acid residues in length;

L 2 is 3 to 14 amino acid residues in length;

L 3 is 1 to 8 amino acid residues in length; and

L 4 is 1 to 3 amino acid residues in length;

and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

6. An antibody-like binding protein comprising two polypeptide chains that form two antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:

V L1 -L 1 -V L2 -L 2 -C L   [I]

and a second polypeptide chain has a structure represented by the formula:

V H2 -L 3 -V H1 -L 4 -C H1   [II]

wherein:

V L1 is a first immunoglobulin light chain variable domain;

V L2 is a second immunoglobulin light chain variable domain;

V H1 is a first immunoglobulin heavy chain variable domain;

V H2 is a second immunoglobulin heavy chain variable domain;

C L is an immunoglobulin light chain constant domain;

C H1 is the immunoglobulin C H1 heavy chain constant domain; and

L 1 , L 2 , L 3 , and L 4 are amino acid linkers;

wherein:

L 1 is 3 to 12 amino acid residues in length;

L 2 is 3 to 14 amino acid residues in length;

L 3 is 1 to 8 amino acid residues in length; and

L 4 is 1 to 3 amino acid residues in length;

and wherein the first and second polypeptides form a cross-over light chain-heavy chain pair.

7. The antibody-like binding protein of claim 5 or 6 ,

wherein:

L 1 is 5 to 10 amino acid residues in length;

L 2 is 5 to 8 amino acid residues in length;

L 3 is 1 to 5 amino acid residues in length; and

L 4 is 1 to 2 amino acid residues in length.

8. The antibody-like binding protein of claim 5 or 6 , wherein:

L 1 is 7 amino acid residues in length;

L 2 is 5 amino acid residues in length;

L 3 is 1 amino acid residue in length; and

L 4 is 2 amino acid residues in length.

9. An antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, wherein two polypeptide chains have a structure represented by the formula:

V L1 -L 1 -V L2 -L 2 -C L   [I]

and two polypeptide chains have a structure represented by the formula:

V H2 -L 3 -V H1 -L 4 -C H1 -Fc  [II]

wherein:

V L1 is a first immunoglobulin light chain variable domain;

V L2 is a second immunoglobulin light chain variable domain;

V H1 is a first immunoglobulin heavy chain variable domain;

V H2 is a second immunoglobulin heavy chain variable domain;

C L is an immunoglobulin light chain constant domain;

C H1 is the immunoglobulin C H1 heavy chain constant domain;

Fc is the immunoglobulin hinge region and C H2 , C H3 immunoglobulin heavy chain constant domains; and

L 1 , L 2 , L 3 , and L 4 are amino acid linkers;

wherein:

L 1 is 1 to 3 amino acid residues in length;

L 2 is 1 to 4 amino acid residues in length;

L 3 is 2 to 15 amino acid residues in length; and

L 4 is 2 to 15 amino acid residues in length;

and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

10. An antibody-like binding protein comprising two polypeptide chains that form two antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:

V L1 -L 1 -V L2 -L 2 -C L   [I]

and a second polypeptide chain has a structure represented by the formula:

V H2 -L 3 -V H1 -L 4 -C H1   [II]

wherein:

V L1 is a first immunoglobulin light chain variable domain;

V L2 is a second immunoglobulin light chain variable domain;

V H1 is a first immunoglobulin heavy chain variable domain;

V H2 is a second immunoglobulin heavy chain variable domain;

C L is an immunoglobulin light chain constant domain;

C H1 is the immunoglobulin C H1 heavy chain constant domain; and

L 1 , L 2 , L 3 , and L 4 are amino acid linkers;

wherein:

L 1 is 1 to 3 amino acid residues in length;

L 2 is 1 to 4 amino acid residues in length;

L 3 is 2 to 15 amino acid residues in length; and

L 4 is 2 to 15 amino acid residues in length;

and wherein the first and second polypeptides form a cross-over light chain-heavy chain pair.

11. The antibody-like binding protein of claim 9 or 10 , wherein:

L 1 is 1 to 2 amino acid residues in length;

L 2 is 1 to 2 amino acid residues in length;

L 3 is 4 to 12 amino acid residues in length; and

L 4 is 2 to 12 amino acid residues in length.

12. The antibody-like binding protein of claim 9 or 10 , wherein:

L 1 is 1 amino acid residue in length;

L 2 is 2 amino acid residues in length;

L 3 is 7 amino acid residues in length; and

L 4 is 5 amino acid residues in length.

13. The antibody-like binding protein of any one of claim 1 , 2 , 5 , 6 , 9 , or 10 , wherein the binding protein is capable of specifically binding one or more antigen targets.

14. The antibody-like binding protein of claim 13 , wherein the one or more antigen targets is selected from the group consisting of B7.1, B7.2, BAFF, BlyS, C3, C5, CCL11 (eotaxin), CCL15 (MIP-1d), CCL17 (TARC), CCL19 (MIP-3b), CCL2 (MCP-1), CCL20 (MIP-3a), CCL21 (MIP-2), SLC, CCL24 (MPIF-2/eotaxin-2), CCL25 (TECK), CCL26 (eotaxin-3), CCL3 (MIP-la), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CD3, CD19, CD20, CD24, CD40, CD40L, CD80, CD86, CDH1 (E-cadherin), Chitinase, CSF1 (M-CSF), CSF2 (GM-CSF), CSF3 (GCSF), CTLA4, CX3CL1 (SCYD1), CXCL12 (SDF1), CXCL13, EGFR, FCER1A, FCER2, HER2, IGF1R, IL-1, IL-12, IL13, IL15, IL17, IL18, IL1A, IL1B, IL1F10, IL1β, IL2, IL4, IL6, IL7, IL8, IL9, IL12/23, IL22, IL23, IL25, IL27, IL35, ITGB4 (b 4 integrin), LEP (leptin), MHC class II, TLR2, TLR4, TLR5, TNF, TNFα, TNFSF4 (OX40 ligand), TNFSF5 (CD40 ligand), Toll-like receptors, TREM1, TSLP, TWEAK, XCR1 (GPR5/CCXCR1), DNGR-1(CLEC91), and HMGB1.

15. The antibody-like binding protein of claim 13 , wherein the one or more antigen targets is selected from the group consisting of IL4 and IL13.

16. The antibody-like binding protein of any one of claim 1 , 2 , 5 , 6 , 9 , or 10 , wherein the binding protein is bispecific and capable of binding two different antigen targets.

17. The antibody-like binding protein of claim 16 , wherein the two different antigen targets are selected from the group consisting of IL4 and IL13, IGF1R and HER2, IGF1R and EGFR, EGFR and HER2, BK and IL13, PDL-1 and CTLA-4, CTLA4 and MHC class II, IL-12 and IL-18, IL-1α and IL-1β, TNFα and IL12/23, TNFα and IL-12p40, TNFα and IL1β, TNFα and IL-23, and IL17 and IL23.

18. The antibody-like binding protein of claim 16 , wherein the two different antigen targets are IL4 and IL13.

19. The antibody-like binding protein of any one of claim 1 , 2 , 5 , 6 , 9 , or 10 , wherein the binding protein is capable of inhibiting the function of one or more antigen targets.

20. The antibody-like binding protein of any one of claim 1 , 2 , 5 , 6 , 9 , or 10 , wherein at least one of the linkers selected from the group consisting of L 1 , L 2 , L 3 , and L 4 contains at least one cysteine residue.

21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody-like binding protein of any one of claim 1 , 2 , 5 , 6 , 9 , or 10 .